Motilal Oswal is bullish on Hindustan Unilever recommended buy rating on the stock with a target price of Rs 3080 in its research report dated October 21, 2022.
Posts tagged MC
Buy Hindustan Unilever; target of Rs 3080: Motilal Oswal (24-10-2022)
Buy SBI Life Insurance; target of Rs 1500: Motilal Oswal (24-10-2022)
Motilal Oswal is bullish on SBI Life Insurance recommended buy rating on the stock with a target price of Rs 1500 in its research report dated October 22, 2022.
Buy V.I.P. Industries; target of Rs 1009: Prabhudas Lilladher (23-10-2022)
Prabhudas Lilladher is bullish on V.I.P. Industries has recommended buy rating on the stock with a target price of Rs 1009 in its research report dated October 22, 2022.
Buy ICICI Bank; target of Rs 1090: Prabhudas Lilladher (23-10-2022)
Prabhudas Lilladher is bullish on ICICI Bank has recommended buy rating on the stock with a target price of Rs 1090 in its research report dated October 23, 2022.
Buy UPL; target of Rs 1020: Prabhudas Lilladher (23-10-2022)
Prabhudas Lilladher is bullish on UPL has recommended buy rating on the stock with a target price of Rs 1020 in its research report dated October 23, 2022.
Buy UPL; target of Rs 1020: Prabhudas Lilladher (23-10-2022)
Prabhudas Lilladher is bullish on UPL has recommended buy rating on the stock with a target price of Rs 1020 in its research report dated October 23, 2022.
Buy UPL; target of Rs 1020: Prabhudas Lilladher (23-10-2022)
Prabhudas Lilladher is bullish on UPL has recommended buy rating on the stock with a target price of Rs 1020 in its research report dated October 23, 2022.
Accumulate Kotak Mahindra Bank; target of Rs 2100: Prabhudas Lilladher (23-10-2022)
Prabhudas Lilladher recommended accumulate rating on Kotak Mahindra Bank with a target price of Rs 2100 in its research report dated October 23, 2022.
Laurus Labs: Anti-retroviral business disappoints but synthesis-led growth intact (22-10-2022)
Capex execution will be key to the company’s growth prospects; diversification initiatives should be supportive
Navin Fluorine: Pick-up in demand from pharma innovators a key watch (21-10-2022)
Valuation is quite rich and investors should wait for a better opportunity to accumulate this stock